Successful delayed thrombolysis for cerebral venous and dural sinus thrombosis: a case report and review of the literature

J Stroke Cerebrovasc Dis. 2008 Nov-Dec;17(6):429-32. doi: 10.1016/j.jstrokecerebrovasdis.2008.07.001.

Abstract

Cerebral venous and dural sinus thrombosis (CVDST) is a rare but not uncommon life-threatening disease accounting for less than 1% of stroke, affecting people of any age group, predominantly the extremes of age. CVDST carries a variable prognosis: although the majority of cases are associated with complete recovery, outcome may be fatal in less than 10% of patients. Thrombolysis has been widely used in CVDST in patients with rapidly deteriorating symptoms who fail to improve despite adequate anticoagulation, but the exact therapeutic time window remains unclear. We report a case of CVDST with rapid clinical deterioration despite therapeutic anticoagulation treated with direct endovascular thrombolysis with intravenous recombinant tissue plasminogen activator 1 week after presentation with complete recovery, and we present a review of the literature on the efficacy and safety of thrombolysis in CVDST.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anticoagulants / administration & dosage
  • Cerebral Angiography
  • Cerebral Veins / drug effects*
  • Cerebral Veins / physiopathology
  • Coma / etiology
  • Coma / physiopathology
  • Disease Progression
  • Female
  • Fibrinolytic Agents / administration & dosage
  • Heparin / administration & dosage
  • Humans
  • Injections, Intravenous
  • Recovery of Function / drug effects
  • Recovery of Function / physiology
  • Sinus Thrombosis, Intracranial / drug therapy*
  • Sinus Thrombosis, Intracranial / physiopathology
  • Thrombolytic Therapy / methods
  • Thrombolytic Therapy / standards*
  • Tissue Plasminogen Activator / administration & dosage*
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Vascular Surgical Procedures
  • Venous Thrombosis / drug therapy*
  • Venous Thrombosis / physiopathology

Substances

  • Anticoagulants
  • Fibrinolytic Agents
  • Heparin
  • Tissue Plasminogen Activator